Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study’s pre-crossover/booster phase were previously reported. This phase 2a/b clinica...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2425147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687399097958400 |
|---|---|
| author | Vivek Shinde Anthonet Lombard Koen Zaheer Hoosain Moherndran Archary Qasim Bhorat Lee Fairlie Umesh Lalloo Mduduzi S. L. Masilela Dhayendre Moodley Sherika Hanley Leon Frederik Fouche Cheryl Louw Michele Tameris Nishanta Singh Ameena Goga Keertan Dheda Coert Grobbelaar Natasha Joseph Johan J. Lombaard Rosie Mngqibisa As’ad Ebrahim Bhorat Gabriella Benadé Natasha Lalloo Anna Pitsi Pieter-Louis Vollgraaff Angelique Luabeya Aliasgar Esmail Friedrich G. Petrick Aylin Oommen Jose Sharne Foulkes Khatija Ahmed Asha Thombrayil Dishiki Kalonji Shane Cloney-Clark Mingzhu Zhu Chijioke Bennett Gary Albert Alex Marcheschi Joyce S. Plested Susan Neal Gordon Chau Iksung Cho Louis Fries Greg M. Glenn Shabir A. Madhi |
| author_facet | Vivek Shinde Anthonet Lombard Koen Zaheer Hoosain Moherndran Archary Qasim Bhorat Lee Fairlie Umesh Lalloo Mduduzi S. L. Masilela Dhayendre Moodley Sherika Hanley Leon Frederik Fouche Cheryl Louw Michele Tameris Nishanta Singh Ameena Goga Keertan Dheda Coert Grobbelaar Natasha Joseph Johan J. Lombaard Rosie Mngqibisa As’ad Ebrahim Bhorat Gabriella Benadé Natasha Lalloo Anna Pitsi Pieter-Louis Vollgraaff Angelique Luabeya Aliasgar Esmail Friedrich G. Petrick Aylin Oommen Jose Sharne Foulkes Khatija Ahmed Asha Thombrayil Dishiki Kalonji Shane Cloney-Clark Mingzhu Zhu Chijioke Bennett Gary Albert Alex Marcheschi Joyce S. Plested Susan Neal Gordon Chau Iksung Cho Louis Fries Greg M. Glenn Shabir A. Madhi |
| author_sort | Vivek Shinde |
| collection | DOAJ |
| description | COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study’s pre-crossover/booster phase were previously reported. This phase 2a/b clinical trial in South Africa (2019nCoV-501/NCT04533399) revisits 1:1 randomly assigned HIV-negative adults (18–84 years) and medically stable PLWH (18–64 years) who previously received two NVX-CoV2373 doses (5 μg recombinant Spike protein with 50 μg Matrix-M™ adjuvant) or placebo. During the 6-month blinded crossover/booster phase, NVX-CoV2373 recipients could receive a single NVX-CoV2373 booster dose and placebo recipients a 2-dose NVX-CoV2373 primary series. NVX-CoV2373 safety and immunogenicity were assessed according to prior SARS-CoV-2 infection and HIV status. Post-crossover, 1900/3793 NVX-CoV2373 recipients were assigned another dose, and 1893/3793 placebo recipients were assigned NVX-CoV2373 primary series. Approximately 56% of the participants were SARS-CoV-2–seropositive (“seropositive”) at crossover (6% PLWH). In seropositive participants (HIV-negative and PLWH), booster-dose anti-spike IgG, MN50 and hACE2 inhibition responses increased to similar levels, exceeding those in seronegative participants. In primary-series and booster cohorts, seronegative PLWH showed higher neutralizing responses (4.9- to 5.5-fold, respectively) versus peak pre-crossover primary-series responses. The safety profile was similar among the pre-crossover/booster phase groups; solicited and unsolicited adverse events were infrequent in all groups. A single NVX-CoV2373 booster dose substantially increased antibodies. All baseline seropositive participants showed higher immune responses than seronegative participants. These findings support use of NVX-CoV2373, including in immunocompromised individuals. |
| format | Article |
| id | doaj-art-90d0e4a6be6e439a95268e85ec023ca2 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-90d0e4a6be6e439a95268e85ec023ca22025-08-20T03:22:21ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2425147Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trialVivek Shinde0Anthonet Lombard Koen1Zaheer Hoosain2Moherndran Archary3Qasim Bhorat4Lee Fairlie5Umesh Lalloo6Mduduzi S. L. Masilela7Dhayendre Moodley8Sherika Hanley9Leon Frederik Fouche10Cheryl Louw11Michele Tameris12Nishanta Singh13Ameena Goga14Keertan Dheda15Coert Grobbelaar16Natasha Joseph17Johan J. Lombaard18Rosie Mngqibisa19As’ad Ebrahim Bhorat20Gabriella Benadé21Natasha Lalloo22Anna Pitsi23Pieter-Louis Vollgraaff24Angelique Luabeya25Aliasgar Esmail26Friedrich G. Petrick27Aylin Oommen Jose28Sharne Foulkes29Khatija Ahmed30Asha Thombrayil31Dishiki Kalonji32Shane Cloney-Clark33Mingzhu Zhu34Chijioke Bennett35Gary Albert36Alex Marcheschi37Joyce S. Plested38Susan Neal39Gordon Chau40Iksung Cho41Louis Fries42Greg M. Glenn43Shabir A. Madhi44Research and Development, Novavax, Inc, Gaithersburg, MD, USASouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaResearch and Development, Josha Research Centre, Bloemfontein, Free State, South AfricaPaediatric Infectious Diseases Unit, University of KwaZulu-Natal, Durban, South AfricaResearch and Development, Soweto Clinical Trials Centre, Johannesburg, South AfricaWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaRespiratory and Critical Care Unit, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South AfricaResearch and Development, Setshaba Research Centre, Tshwane, South AfricaDepartment of Obstetrics and Gynaecology, University of KwaZulu-Natal, Durban, South AfricaCentre for the AIDS Programme of Research in South Africa (CAPRISA), and Department of Family Medicine, University of KwaZulu-Natal, Durban, South AfricaResearch and Development, Limpopo Clinical Research Initiative, Thabazimbi, South AfricaResearch and Development, Madibeng Centre for Research, Brits, South AfricaSouth African TB Vaccine Initiative, University of Cape Town, Cape Town, South AfricaSouth African Medical Research Council, HIV and other Infectious Diseases Research Unit (HIDRU) and, Health Systems Research Unit, Durban, South AfricaSouth African Medical Research Council, HIV and other Infectious Diseases Research Unit (HIDRU) and, Health Systems Research Unit, Durban, South AfricaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, Cape Town, South AfricaAurum Institute, University of Pretoria, Pretoria, South AfricaResearch and Development, PEERMED Clinical Trial Centre, Kempton Park, South AfricaResearch and Development, Josha Research Centre, Bloemfontein, Free State, South AfricaPaediatric Infectious Diseases Unit, University of KwaZulu-Natal, Durban, South AfricaResearch and Development, Soweto Clinical Trials Centre, Johannesburg, South AfricaWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaRespiratory and Critical Care Unit, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South AfricaResearch and Development, Setshaba Research Centre, Tshwane, South AfricaResearch and Development, Limpopo Clinical Research Initiative, Thabazimbi, South AfricaSouth African TB Vaccine Initiative, University of Cape Town, Cape Town, South AfricaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, Cape Town, South AfricaResearch and Development, MERC Research, Middelburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaResearch and Development, Josha Research Centre, Bloemfontein, Free State, South AfricaResearch and Development, Setshaba Research Centre, Tshwane, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USAResearch and Development, Novavax, Inc, Gaithersburg, MD, USASouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaCOVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study’s pre-crossover/booster phase were previously reported. This phase 2a/b clinical trial in South Africa (2019nCoV-501/NCT04533399) revisits 1:1 randomly assigned HIV-negative adults (18–84 years) and medically stable PLWH (18–64 years) who previously received two NVX-CoV2373 doses (5 μg recombinant Spike protein with 50 μg Matrix-M™ adjuvant) or placebo. During the 6-month blinded crossover/booster phase, NVX-CoV2373 recipients could receive a single NVX-CoV2373 booster dose and placebo recipients a 2-dose NVX-CoV2373 primary series. NVX-CoV2373 safety and immunogenicity were assessed according to prior SARS-CoV-2 infection and HIV status. Post-crossover, 1900/3793 NVX-CoV2373 recipients were assigned another dose, and 1893/3793 placebo recipients were assigned NVX-CoV2373 primary series. Approximately 56% of the participants were SARS-CoV-2–seropositive (“seropositive”) at crossover (6% PLWH). In seropositive participants (HIV-negative and PLWH), booster-dose anti-spike IgG, MN50 and hACE2 inhibition responses increased to similar levels, exceeding those in seronegative participants. In primary-series and booster cohorts, seronegative PLWH showed higher neutralizing responses (4.9- to 5.5-fold, respectively) versus peak pre-crossover primary-series responses. The safety profile was similar among the pre-crossover/booster phase groups; solicited and unsolicited adverse events were infrequent in all groups. A single NVX-CoV2373 booster dose substantially increased antibodies. All baseline seropositive participants showed higher immune responses than seronegative participants. These findings support use of NVX-CoV2373, including in immunocompromised individuals.https://www.tandfonline.com/doi/10.1080/21645515.2024.2425147Novavax, Inc.the Bill & Melinda Gates Foundationand the Coalition for Epidemic Preparedness Innovations |
| spellingShingle | Vivek Shinde Anthonet Lombard Koen Zaheer Hoosain Moherndran Archary Qasim Bhorat Lee Fairlie Umesh Lalloo Mduduzi S. L. Masilela Dhayendre Moodley Sherika Hanley Leon Frederik Fouche Cheryl Louw Michele Tameris Nishanta Singh Ameena Goga Keertan Dheda Coert Grobbelaar Natasha Joseph Johan J. Lombaard Rosie Mngqibisa As’ad Ebrahim Bhorat Gabriella Benadé Natasha Lalloo Anna Pitsi Pieter-Louis Vollgraaff Angelique Luabeya Aliasgar Esmail Friedrich G. Petrick Aylin Oommen Jose Sharne Foulkes Khatija Ahmed Asha Thombrayil Dishiki Kalonji Shane Cloney-Clark Mingzhu Zhu Chijioke Bennett Gary Albert Alex Marcheschi Joyce S. Plested Susan Neal Gordon Chau Iksung Cho Louis Fries Greg M. Glenn Shabir A. Madhi Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial Human Vaccines & Immunotherapeutics Novavax, Inc. the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations |
| title | Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial |
| title_full | Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial |
| title_fullStr | Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial |
| title_full_unstemmed | Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial |
| title_short | Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial |
| title_sort | immunogenicity and safety following a homologous booster dose of a sars cov 2 recombinant spike protein vaccine with matrix mtm adjuvant nvx cov2373 versus a primary series in people living with and without hiv 1 infection in south africa a randomized crossover phase 2a 2b trial |
| topic | Novavax, Inc. the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2425147 |
| work_keys_str_mv | AT vivekshinde immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT anthonetlombardkoen immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT zaheerhoosain immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT moherndranarchary immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT qasimbhorat immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT leefairlie immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT umeshlalloo immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT mduduzislmasilela immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT dhayendremoodley immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT sherikahanley immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT leonfrederikfouche immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT cheryllouw immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT micheletameris immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT nishantasingh immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT ameenagoga immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT keertandheda immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT coertgrobbelaar immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT natashajoseph immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT johanjlombaard immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT rosiemngqibisa immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT asadebrahimbhorat immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT gabriellabenade immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT natashalalloo immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT annapitsi immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT pieterlouisvollgraaff immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT angeliqueluabeya immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT aliasgaresmail immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT friedrichgpetrick immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT aylinoommenjose immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT sharnefoulkes immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT khatijaahmed immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT ashathombrayil immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT dishikikalonji immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT shanecloneyclark immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT mingzhuzhu immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT chijiokebennett immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT garyalbert immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT alexmarcheschi immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT joycesplested immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT susanneal immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT gordonchau immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT iksungcho immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT louisfries immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT gregmglenn immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial AT shabiramadhi immunogenicityandsafetyfollowingahomologousboosterdoseofasarscov2recombinantspikeproteinvaccinewithmatrixmtmadjuvantnvxcov2373versusaprimaryseriesinpeoplelivingwithandwithouthiv1infectioninsouthafricaarandomizedcrossoverphase2a2btrial |